Want to see KURA full AI Analyst Report?
KURA Stock Chart & Stats
$10.39
-$0.06(-0.57%)
At close: 4:00 PM EDT
$10.39
-$0.06(-0.57%)
Day’s Range― - ―
52-Week Range$6.95 - $12.85
Previous CloseN/A
Volume1.14M
Average Volume (3M)1.51M
Market Cap
$1.00B
Enterprise Value$480.17
Total Cash (Recent Filing)$519.02M
Total Debt (Recent Filing)$24.45M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Oct 29, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.37
Shares Outstanding88,960,620
10 Day Avg. Volume1,083,218
30 Day Avg. Volume1,513,902
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)5.23
Price to Sales (P/S)13.50
P/FCF Ratio-12.89
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.22Price Target Upside171.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.49
Revenue Forecast (FY)$95.04M
Bulls Say, Bears Say
Bulls Say
Early Commercial AdoptionCOMZIFTI has established an initial commercial foothold in NPM1-mutant AML. Growing starts and prescriptions, combined with majority new-start share, indicate product adoption that could support a durable revenue base as market penetration expands.
Clinical DifferentiationStrong response data across the KOMET program support ziftomenib’s potential clinical differentiation in genetically defined AML. Durable efficacy could improve prescribing, expand eligible use, and strengthen the commercial value of the lead product.
Funding And Partnership SupportKyowa Kirin support and projected collaboration revenue provide meaningful funding visibility for the lead AML program. This reduces immediate financing pressure and gives Kura time to reach pivotal clinical milestones without relying solely on new equity.
Bears Say
Persistent Operating LossesKura remains structurally unprofitable despite emerging product revenue and strong gross margins. Large operating losses require continued external funding and make eventual profitability dependent on successful commercialization and substantial revenue growth.
Cash Burn And Balance Sheet PressureNegative cash generation and a sizeable decline in liquidity show that development and commercial investment are consuming resources. If burn persists or milestones are delayed, Kura may need additional funding, creating dilution and financial flexibility risk.
Long-Dated Clinical Execution RiskMajor value-creating clinical readouts remain years away, leaving substantial uncertainty around trial execution, timing, efficacy durability, and real-world outcomes. Delays or weaker results could postpone broader adoption and extend the company’s funding needs.
Kura Oncology News
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $6.95 and its highest was $12.85 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is $1.00B.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Oct 29, 2026 which is in 71 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Aug 12, 2026. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$0.877 by $0.107.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.83.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 88,960,620 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.77 in its last earnings report, beating expectations of -$0.877. Following the earnings report the stock price went up 1.509%.
Which hedge fund is a major shareholder of Kura Oncology?
Currently, no hedge funds are holding shares in KURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kura Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.22 (171.63% Upside)
$28.22 (171.63% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 203.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 8.9%
Last 30 Days ▲ 8.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.87%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc. (KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology therapeutics for the treatment of cancer. The company’s activities center on advancing a pipeline of small-molecule drug candidates through clinical development, with a focus on genetically defined cancers and targeted approaches intended to address specific oncogenic drivers or resistance mechanisms.
KURA Company Deck
KURA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong early commercial traction for COMZIFTI (notable revenue, majority share of new patient starts, high Q/Q growth in starts and prescriptions), robust clinical data across Ziftomenib and promising darlifarnib combination signals in multiple solid tumor settings. Financials show solid funding runway with Kyowa Kirin support but also reflect increased commercial spend, a declining cash balance since year‑end, and a YoY decline in collaboration revenue. Competitive noise around market share and the multi‑year timelines to pivotal readouts add uncertainty. Overall, positive operational and clinical momentum is balanced against near‑term financial and competitive considerations.View all KURA earnings summariesKURA Stock 12 Month Forecast
Average Price Target
$28.22
▲(171.63% Upside)
Technical Analysis
Geron
―
CytomX Therapeutics
―
Zentalis Pharmaceuticals
―
Oric Pharmaceuticals
―
Prelude Therapeutics
―
Ownership Overview
2.48% Insiders
10.74% Mutual Funds
40.99% Other Institutional Investors
28.78% Public Companies and Individual Investors